All News

All News2019-03-07T14:47:33+00:00

Join us in New York City for DCAT Week 2017 – March 20-23

March 6, 2017

Join us in New York City for DCAT Week 2017 – March 20-23

Join us in New York City for DCAT Week 2017 on March 20-23, 2017. DCAT Week is the premier business development event for companies engaged in pharmaceutical development and manufacturing and related industries. It is organized and hosted by the Drug, Chemical & Associated Technologies Association (DCAT) to assist its member companies with their business development objectives. The event’s unique model brings together members for high-level strategic meetings with key decision makers, timely educational programs and important networking opportunities.

March 6th, 2017|News|

DCAT Announces New Advisory Council Member

November 1, 2016

PRESS RELEASE

DCAT Announces New Advisory Council Member

Robbinsville, NJ, November 1, 2016 – The Drug, Chemical & Associated Technology Association (DCAT) is pleased to announce that Oliver Technow, president of BioVectra, Inc., has been elected by the membership to serve on DCAT’s Advisory Council for a three-year term beginning November 1, 2016.

“We look forward to Mr. Technow’s contributions to the DCAT organization,” said Executive Director Margaret Timony. “He brings valuable industry experience and leadership skills that will help shape and support the organization’s programs, events and projects.”

More information on new DCAT Leadership can be found here.

About DCAT
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing. With over 400 corporate members, DCAT is headquartered in Robbinsville, New Jersey.

March 5th, 2017|News|

BioVectra Goes Global

Some 45 years ago, Regis Duffy saw large-scale opportunity in the pharmaceutical and diagnostic marketplace and created the origins of BioVectra Inc. in a Charlottetown garage. In the ensuing decades, BioVectra has earned global recognition and a key role in Atlantic Canada’s bioscience sector.

View Article

February 26th, 2017|Articles|

Joint Venture Contract Services – A CDMO’S Approach To Being A True Partner

September 20, 2016

Joint Venture Contract Services – A CDMO’S Approach To Being A True Partner

The active pharmaceutical ingredient (API) is the key functional component of a pharmaceutical formulation, rendering efficacy to the final drug product. Driven by the aging population, public and government demands for affordable drugs, reimbursement pressure and expansion of the emerging market, the pharmaceutical market is expanding rapidly. With this, the global market for APIs will rise steadily, meeting the increased need for medicines across the board. The market is expected to reach $198.8 billion by 2022, growing from $121.4 billion in 2014 at a compound annual growth rate (CAGR) of 6.4%.

View Article

September 20th, 2016|Articles|

What makes BioVectra a “Leader in today’s competitive CDMO market.”

June 8, 2016

What makes BioVectra a “Leader in today’s competitive CDMO market.”

BioVectra’s new President Oliver Technow shares his insight story about what makes BioVectra a “Leader in today’s competitive CDMO market.”  BioVectra started its journey more than 45 years ago as a fine chemical and enzyme producer for the pharmaceutical and diagnostic industries. Today, with four facilities and roughly 300 employees in Eastern Canada, BioVectra is focused on partnering in innovative ways in the long-term manufacturing and development of APIs and drug substances.

View Article

June 8th, 2016|Articles|

Establishing Specialized CDMO Capabilities for the Production of Advanced Therapies

May 20, 2016

Establishing Specialized CDMO Capabilities for the Production of Advanced Therapies

To be successful, contract development and manufacturing organizations (CDMOs) must be forward thinking — constantly anticipating the future needs of potential customers and investing in state-of-the-art facilities, equipment, and technologies.

View Article

May 20th, 2016|Articles|

BioVectra – Hiring Practices – The Employment Journey on PEI

January 29, 2016

BioVectra – Hiring Practices – The Employment Journey on PEI

BioVectra is a custom manufacturer of pharmaceutical ingredients for pharma companies.  The company started when Dr. Regis Duffy, Dean of Science at UPEI, wanted to create summer employment for his students. Now, 45 years later, BioVectra is a wholly-owned subsidiary of a publicly-traded multinational pharmaceutical company with employees working primarily on PEI, as well as Nova Scotia and elsewhere.  “We have 260 talented people with diverse backgrounds in organic chemistry, polymer chemistry, biochemistry, molecular biology, and many fields of engineering, as well as specialists in manufacturing and quality assurance,” says Heather Delage, who has worked for BioVectra for 25 years.

View Article

January 29th, 2016|Articles|

BioVectra Announces Acquistion of Former Sunovion (Sepracor) Facility

June 23, 2014

BioVectra Announces Acquisition of Former Sunovion (Sepracor) Facility

BioVectra, a specialized cGMP manufacturer, and developer of pharmaceutical ingredients has announced today that it has agreed to purchase the previous Sepracor Canada Limited facility at Windsor, Nova Scotia, for an undisclosed sum.

View Article

June 23rd, 2014|News|

BioVectra Starts Construction to Expand Charlottetown Facility

June 11, 2014

BioVectra Starts Construction to Expand Charlottetown Facility

BioVectra, a specialized manufacturer and developer of pharmaceutical ingredients for the global marketplace, has commenced the expansion of one of its Prince Edward Island facilities, located at 11 Aviation Avenue, adjacent to the Charlottetown airport.

View Article

June 11th, 2014|News|

Risk Management in Financing of Capital Expansions

May 1, 2014

Risk Management in Financing of Capital Expansions

BioVectra Inc. is an eastern Canadian contract manufacturing organization (CMO) with expertise in both synthetic chemistry and biomanufacturing techniques. In recent years, it has obtained specialized knowledge in the production of highly potent small molecules from fermentation and functionalized methoxy-poly (ethylene glycol) products (MPEGs). The focus of BioVectra’s contract manufacturing business is the transfer and scale-up of processes for manufacturing its clients’ products under current good manufacturing practices (cGMPs) as appropriate for the clinical stage of each product.

View Article

May 1st, 2014|Articles|

BioVectra Spending $3.8 Million on Expansion

June 14, 2014

BioVectra Spending $3.8 Million on Expansion

An Island company that has been in business for more than 40 years is growing as BioVectra invests $3.8 million to expand one of its facilities in Charlottetown.

View Article

May 1st, 2014|Articles|

BioVectra Named Agent of Reagent Proteins’ Products

June 25, 2013

BioVectra Named Agent of Reagent Proteins’ Products

BioVectra announced today a new agreement naming BioVectra as a non-exclusive agent of Reagent Proteins in North America and Europe. BioVectra will provide its customers access to Reagent Proteins’ unique range of over 5,000 catalog protein products; as well as actively promoting Reagent Proteins’ capabilities through its agency network and directly to its key customers, including the potential for custom projects.

View Article

June 25th, 2013|News|